Annatto-derived GG for Statin-associated Myopathy
Texas Tech University Health Sciences Center · NCT05312424
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 40+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 1, Phase 2
- Target enrollment
- 95
- US sites recruiting
- 1
- Study start
- July 15, 2022
- Record last updated
- September 11, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
To evaluate the effects of 3-months annatto-derived geranylgeraniol (GG) supplementation on statin-associated skeletal muscle health.
Being studied: Placebo; Low GG; High GG
Conditions: Myopathy; Primary
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age ≥40 of either sex
- Statin-treated patients with muscle pain alone or accompanied by other symptoms.
- Patients currently receiving a statin who developed new-onset myalgias in within 90 day of initiation or a dosage increase
Exclusion Criteria
- Malignancy or significant neurological or psychiatric disturbances, including alcohol or drug abuse.
- Woman who is pregnant, breastfeeding, or of childbearing potential and not taking adequate contraceptive precautions.
- Had CoQ10 supplement one month before starting the study.
- Genetic musculoskeletal and neurologic disorder known to affect skeletal muscle metabolism
- Had steroid medication one month before starting the study.
Recruiting US locations
Texas Tech University Health Sciences Center
Lubbock, TX 79430
Site contact: Chwan-Li (Leslie) Shen, PhD · 806-743-2815 · Leslie.Shen@ttuhsc.edu
Study contacts (from the official record)
- Chwan-Li (Leslie) Shen, PhD · 8067432815 · leslie.shen@ttuhsc.edu
Similar studies in Texas
All healthy volunteers studies in Texas →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of LY4355756 in Healthy Participants
Eli Lilly and Company
- Location
- Dallas, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- San Antonio, TX + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- San Antonio, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Radiprodil in Participants With Hepatic Impairment
GRIN Therapeutics, Inc.
- Location
- DeSoto, TX + 1 other US site
- Eligibility basics
- Ages 18–75